Clinical trials: Obstructive Pulmonary Diseases
Chronic Obstructive Pulmonary Disease, Heart Failure
Adjusting to Chronic Conditions Using Education, Support, and Skills
The current study seeks to test the effectiveness of a talk-therapy intervention designed to better meet the needs of chronically ill Veterans.
- Conditions
- Chronic Obstructive Pulmonary Disease, Heart Failure, Anxiety, Depression
- Trial name
- ACCESS (NCT01149772)
- Testing
- ACCESS
- Where
- 2 sites in United States
- Volunteers
- 302 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease
Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients
The aim of this study was to compare the tiotropium Respimat Soft Mist Inhaler and the HandiHaler in terms of their effects on sleeping oxygen saturation (SaO2) and sleep quality in patients with COPD.
- Trial name
- NCT02331940
- Testing
- tiotropium, Handihaler, Respimat
- Volunteers
- 200 people
- Sponsor
- University of Crete
Asthma
A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children…
- Trial name
- RAINBOW (NCT00384189)
- Testing
- Ciclesonide, Salbutamol
- Where
- 122 sites in Bulgaria, Germany and 7 more
- Volunteers
- 1,080 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD
This is a 24-week, phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The study will have 9 scheduled visits and a telephone contact Follow-up visit one week following the end of study…
- Trial name
- NCT01636713
- Testing
- GSK573719/VI 62.5/25, GSK573719/VI 125/25
- Where
- 44 sites in China, Philippines and 3 more
- Volunteers
- 581 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils…
- Trial name
- NCT02452190
- Testing
- Reslizumab
- Where
- 226 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pulmonary Disease, Chronic Obstructive
Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals.
- Trial name
- LEUKO (NCT00493974)
- Testing
- Zileuton
- Where
- 18 sites in United States
- Volunteers
- 119 people
- Sponsor
- University of Minnesota
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Pulmonary Disease, Chronic Obstructive
Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
Primary objective: To investigate bronchodilator effect and safety of single doses of BI 1744 CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics of BI 1744 CL.
- Trial name
- NCT01809262
- Testing
- single dose of 5 mcg, single dose of 40 mcg, single dose of 20 mcg
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Bronchitis
Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup
Objectives: The objectives of the study was to investigate the bioequivalence between two formulations containing S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys) when administered as single oral dose in two…
- Trial name
- NCT02858193
- Testing
- SCMC-lys powder 1.35 g, Fluifort® syrup
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dompé Farmaceutici S.p.A
COPD
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium…
- Trial name
- NCT03937479
- Where
- 50 sites in United States
- Volunteers
- 416 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Asthma
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)
The CPAP trial is a 3-arm parallel design randomized sham-controlled trial. Participants are randomly assigned in equal allocation to one of three treatments: CPAP 10 cm water (H₂O) (high) vs. CPAP 5 cm H₂O (medium) vs.
- Trial name
- CPAP (NCT01629823)
- Testing
- Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
- Where
- 18 sites in United States
- Volunteers
- 209 people
- Sponsor
- American Lung Association Asthma Clinical Research Centers
Asthma
Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from…
- Trial name
- NCT01128595
- Testing
- FF/GW642444M, GW642444M, Fluticasone Furoate
- Where
- 4 sites in Australia, New Zealand and 1 more
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
COPD
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.
- Trial name
- NCT02465567
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg
- Where
- 741 sites in United States, Argentina and 24 more
- Volunteers
- 8,588 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma Chronic
Azithromycin Treatment for the Airway Microbiome in Asthma
The purpose of this study to determine whether the bacteria inside the lungs of people with asthma can be modified (changed) if they are given an antibiotic and if this change is associated with an improvement in asthma symptoms.
- Trial name
- NCT03736629
- Testing
- Azithromycin
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Chronic Obstructive Pulmonary Disease
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
- Trial name
- GLOW 1 (NCT01005901)
- Testing
- Glycopyrronium bromide
- Where
- 96 sites in United States, Australia and 9 more
- Volunteers
- 1,324 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol (in terms of the spirometry assessment forced expiratory volume in 1 second [FEV1]) over the full 24-h time period
- Trial name
- NCT00615030
- Testing
- Indacaterol, Salmeterol
- Where
- 7 sites in France, Germany and 1 more
- Volunteers
- 96 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice…
- Trial name
- NCT06545500
- Testing
- Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg)
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00567996
- Testing
- Indacaterol 150 μg, Salmeterol 50 μg
- Where
- 128 sites in Canada, Colombia and 13 more
- Volunteers
- 1,002 people
- Sponsor
- Novartis
Asthma
Effects of Reducing Indoor Air Pollution on the Adult Asthmatic Response
This study is about asthma and how the environment affects asthma. Scientists know that air pollution (such as cigarette smoke and other particles in the air) can make asthma symptoms worse.
- Trial name
- INHALE 2 (NCT02153359)
- Testing
- High Efficiency Particulate Air Cleaner
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Johns Hopkins University
Asthma
Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics
This study is designed to evaluate the repeat-dose safety and effectiveness of a bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11 years with asthma.
- Trial name
- NCT00308685
- Testing
- Albuterol
- Where
- 14 sites in United States
- Volunteers
- 95 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.